Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
6.66
-0.40 (-5.67%)
At close: Oct 28, 2025, 4:00 PM EDT
6.66
0.00 (0.02%)
After-hours: Oct 28, 2025, 7:58 PM EDT
Organon & Co. Employees
Organon & Co. had 10,000 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
10,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$628,100
Profits / Employee
$70,000
Market Cap
1.73B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10,000 | 0 | - |
| Dec 31, 2023 | 10,000 | 0 | - |
| Dec 31, 2022 | 10,000 | 700 | 7.53% |
| Dec 31, 2021 | 9,300 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OGN News
- 11 hours ago - The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products - Seeking Alpha
- 1 day ago - Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman - GlobeNewsWire
- 1 day ago - Organon CEO Kevin Ali to resign after probe into wholesaler sales practices - Reuters
- 1 day ago - Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation - Business Wire
- 11 days ago - Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy - Seeking Alpha
- 5 weeks ago - European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire
- 2 months ago - US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire
- 2 months ago - Organon: Valuation Discount Offset By Structural Headwinds - Seeking Alpha